Skip to content
Research Article Open access CC BY 4.0

Atypical Femoral Fractures Following Use of Intravenous Zoledronic Acid After Prior Treatment with Alendronate: A Clinical Practice Series and Opinion

W. Banks Hinshaw, Jennifer P. Schneider

International Journal of Medical and Pharmaceutical Case Reports · pp. 1–11 · Published 11 Sep 2017

10.9734/IJMPCR/2017/36791

Abstract

Aims: An increasing number atypical femoral fractures (AFFs) have been reported in patients who have taken bisphosphonates (BPs) for several years. The European Medicines Agency (EMA) concluded in 2011 that these fractures were a class effect of the drugs. The United States Food & Drug Administration (FDA) updated labels for currently proprietary intravenous Reclast™ (zoledronic acid) have, since 2015, agreed with the EMA opinion. Section 17 of the FDA label states Reclast™ “can cause” these fractures. In this report, we present a clinical sub-class of cases of these fractures illustrating the potential for harm associated with switching BP therapy from an oral agent to Reclast™ (zoledronic acid). Methodology: This paper presents 6 long-term case descriptions of patients, diagnosed with either osteopenia or osteoporosis, incurring a total of ten AFFs following a switch to intravenous zoledronic acid after a much longer and uncomplicated period on oral BPs. One additional case is presented to illustrate that AFFs may also occur with intravenous therapy alone. We have collected these cases directly from the patients and have confirmed all of the details by access to the original medical records, including the radiology and surgery reports. Our opportunity for access is fully described in the article. Results and Opinion: Such a switch has never been investigated in a clinical trial. Based on the pharmacokinetics associated with the intravenous routes for these drugs, we present our reasoning why the untested therapy exemplified should be considered as potentially hazardous. Furthermore, we discuss the reported but rather unremarked wide individual variation in the rate of elimination of intravenously-administered BPs which may be an important factor in determining which individuals are at greatest risk of incurring an AFF.

Reclast atypical fractures alendronate zoledronic acid bisphosphonate pharmacokinetics.

References (26)

  1. 1 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [DOI]
  2. 2 Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis [DOI]
  3. 3 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report [DOI]
  4. 4 Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research [DOI]
  5. 5 Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures [DOI]
  6. 6 BMD at Multiple Sites and Risk of Fracture of Multiple Types: Long-Term Results From the Study of Osteoporotic Fractures [DOI]
  7. 7 Bisphosphonates: A review of their pharmacokinetic properties [DOI]
  8. 8 Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density [DOI]
  9. 9 Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite [DOI]
  10. 10 The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) [DOI]
  11. 11 The laws of bone architecture [DOI]
  12. 12 The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs [DOI]
  13. 13 Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur [DOI]
  14. 14 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis [DOI]
  15. 15 Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases [DOI]
  16. 16 Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis [DOI]
  17. 17 Risk of Atypical Femoral Fracture during and after Bisphosphonate Use [DOI]
  18. 18 Clinical pharmacology of alendronate sodium [DOI]
  19. 19 Structure–Activity Relationships Among the Nitrogen Containing Bisphosphonates in Clinical Use and Other Analogues: Time-Dependent Inhibition of Human Farnesyl Pyrophosphate Synthase [DOI]
  20. 20 Atypical Femur Fractures: 81 Individual Personal Histories [DOI]
  21. 21 Fractures after Long-Term Alendronate Therapy [DOI]
  22. 22 Anti-resorptives in the management of osteoporosis [DOI]
  23. 23 Pitfalls in the Measurement of Bone Mineral Density by Dual Energy X-ray Absorptiometry [DOI]
  24. 24 Intravenous bisphosphonates for postmenopausal osteoporosis.
  25. 25 Bisphosphonate-associated Atypical Fractures that are not “Atypical Femoral Fractures” [DOI]
  26. 26 Bisphosphonate-Associated Bilateral Atraumatic Ulna Fractures [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

37

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.